(Q43890036)

27 November 2017

title

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer (English)

1 reference

27 November 2017

0 references

Dosia Antonadou

1

1 reference

27 November 2017

Marizenia Pepelassi

2

1 reference

27 November 2017

Maria Synodinou

3

1 reference

27 November 2017

Maria Puglisi

4

1 reference

27 November 2017

Nicolas Throuvalas

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

International Journal of Radiation Oncology Biology Physics

27 November 2017

published in

1 reference

27 November 2017

volume

52

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

739-747

1 reference

Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Characterization of radiation sensitivity of human squamous carcinoma A431 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Concurrent chemoradiation in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Pharmacokinetics of WR-2721.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

The effect of overall treatment time of radiation therapy on local control of T1-stage squamous cell carcinoma of the glottis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Avoidance of treatment interruption: an unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2902683-9

7 January 2021

10.1016/S0360-3016(01)02683-9

Identifiers

DOI

1 reference

27 November 2017

1 reference